SCHEMBL2864971

SCHEMBL2864971

Cc1ccc(Cl)cc1-n1nc2c(c1N)c(=O)[nH]c1cc(O)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.45
PDE2A O00408 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TYMS P04818 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
ROCK2 O75116 1/20 0.39
EGFR P00533 1/20 0.39
PRKCG P05129 1/20 0.39
INSR P06213 1/20 0.39
LCK P06239 1/20 0.39
CDK1 P06493 1/20 0.39
CSF1R P07333 1/20 0.39
LYN P07948 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857838 0.88 PARP1 (0.39) CHEK1KDM4EALDH1A1GLAGAA
SCHEMBL2863002 0.86 KDM4E (0.39) PDE2AKDM4EALDH1A1GLAGAA
SCHEMBL2857583 0.84 ADORA3 (0.43) CHEK1GAAFGFR1KDR
SCHEMBL2868587 0.83 KDM4E (0.38) CHEK1KDM4EALDH1A1GLAGAA
SCHEMBL2860224 0.81 RET (0.39) KDM4EALDH1A1GAAHPGDPDPK1
SCHEMBL2864429 0.80 MAOA (0.40) PDE2AKDM4EALDH1A1GLAGAA
SCHEMBL2866719 0.79 PDE2A (0.43) CHEK1PDE2AKDM4EALDH1A1GAA
SCHEMBL2867785 0.78 NTRK1 (0.36) CHEK1KDM4EALDH1A1GLAGAA
SCHEMBL2860242 0.78 TDP2 (0.37) CHEK1KDM4EALDH1A1GLAGAA
SCHEMBL2868597 0.77 TDP2 (0.56) CHEK1KDM4EALDH1A1HPGDROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 CHEK1 605/4885PDE2A 2228/4885KDM4E 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.